Influenza Vaccination

Influenza Vaccination

PEP Topic 
Prevention of Infection: Transplant

Influenza vaccination is the provision of an annual vaccine against influenza with an inactivated influenza virus.  Several organizations have published guidelines on the vaccination of hematopoietic stem cell transplantation recipients (see Centers for Disease Control and Prevention and the European Bone Marrow Transplant Group), and National Comprehensive Cancer Network (NCCN) guidelines provide general principles regarding vaccination use in patients with cancer.  Live attenuated vaccines have the potential to cause disease in compromised patients; however, other vaccines are safe.  The NCCN recommends patient vaccination at least two weeks before receiving immunosuppressive or cytotoxic therapies.  It has been noted that influenza infection causes substantial morbidity and mortality in patients with cancer.  Full recommendations regarding vaccination types and timing can be found in the NCCN guidelines for the prevention of infection.

Recommended for Practice

Guideline/Expert Opinion

Systematic Review/Meta-Analysis